Results 151 to 160 of about 380,265 (306)

Inhibition of proteasome deubiquitinase activity: a strategy to overcome resistance to conventional proteasome inhibitors?

, 2015
Although more traditionally associated with degradation and maintenance of protein homeostasis, the ubiquitin-proteasome system (UPS) has emerged as a critical component in the regulation of cancer cell growth and survival.
Wang, X, Linder, Stig, D´arcy, Padraig,, Wang, Xin, Linder, Stig,, D'Arcy, Padraig,, Selvaraju, Karthik, Mazurkiewicz, Magdalena,, Wang, Xin,, Linder, S,, Gullbo, Joachim, D´arcy, Padraig, D'Arcy, P, Gullbo, J, Gullbo, Joachim,, Mazurkiewicz, Magdalena, Selvaraju, K, Selvaraju, Karthik,, Mazurkiewicz, M,   +18 more
core   +1 more source

Patient therapy outcome modeling in cancer organoids is improved by cancer‐associated fibroblasts and organoid assembly convolution

Molecular Oncology, EarlyView.
Patient‐derived organoids (PDOs) from pancreatic, colorectal, and gastric cancers were used to evaluate standard and experimental therapies. Incorporating cancer‐associated fibroblasts (CAFs) into organoid cultures improved patient therapy outcome prediction.
Marcin Grochowski, Liudmyla Dolinchuk, Michał Jerzak, Albert Gandurski, Tomasz Grochowski, Weronika Wojtyś, Maciej Zadrożny, Wojciech Kaźmierczak, Małgorzata Lenarcik, Marta Matejak‐Górska, Radosław Samsel, Tomasz Olesiński, Dawid Walerych   +12 more
wiley   +1 more source

Low Prevalence of Pre-Treatment and Acquired Drug Resistance to Dolutegravir among Treatment Naïve Individuals Initiating on Tenofovir, Lamivudine and Dolutegravir in Zimbabwe. [PDF]

Viruses, 2023
Kouamou V, Washaya T, Ndhlovu CE, Manasa J.   +3 more
europepmc   +1 more source

Plasma drug activity assay for treatment optimization in tuberculosis patients

, 2011
Item does not contain fulltextLow antituberculosis (TB) drug levels are common, but their clinical significance remains unclear, and methods of measurement are resource intensive.
Scott K. Heysell, Mpagama, S., Kibiki, Gibson S, Houpt, Eric R, Mwaigwisya, S., Heysell, Scott K, Ndusilo, Norah, Pholwat, Suporn, Mwaigwisya, Solomon, Kibiki, G.S., Solomon Mwaigwisya, Suporn Pholwat, Jean Gratz, Mtabho, C., Aarnoutse, R.E., Stellah Mpagama, Heysell, S.K., Rob E. Aarnoutse, Charles Mtabho, Gratz, J., Mpagama, Stellah, Norah Ndusilo, Gratz, Jean, Houpt, E.R., Gibson S. Kibiki, Eric R. Houpt, Mtabho, Charles, Aarnoutse, Rob E, Ndusilo, N., Pholwat, S.   +29 more
core   +1 more source

Epigenetic heterogeneity and plasticity in therapy‐induced tumor states through single‐cell multi‐omics

Molecular Oncology, EarlyView.
Single‐cell multi‐omics reveals epigenetic heterogeneity across therapy‐adaptive tumor states, including quiescent/dormant, drug‐tolerant persister, and EMT‐like phenotypes. By linking regulatory features with state‐associated biomarkers, these approaches inform biomarker‐guided therapeutic strategies for evolving tumors.
Hee Jung Kim, Hwiyeong Lee, Jin Hong, Daechan Park   +3 more
wiley   +1 more source

Acquired drug resistance interferes with the susceptibility of prostate cancer cells to metabolic stress. [PDF]

Cell Mol Biol Lett, 2022
Catapano J, Luty M, Wróbel T, Pudełek M, Piwowarczyk K, Kędracka-Krok S, Siedlar M, Madeja Z, Czyż J.   +8 more
europepmc   +1 more source

PAK1 activation drives divergent resistance mechanisms to aromatase inhibition and tamoxifen in a luminal: A breast cancer model

Molecular Oncology, EarlyView.
Breast cancer remains a major cause of cancer death in women, frequently developing endocrine therapy resistance. This study demonstrates that upregulated p21‐activated kinase 1 (PAK1) activity drives resistance to tamoxifen and long‐term estrogen deprivation in ER+ breast cancer models.
Luisa Schwarzmüller, Janina Müller, Efstathios‐Iason Vlachavas, Lukas Beumers, Lena Fleischhacker, Sara Burmester, Angelika Wörner, Sabine Karolus, Dominic Helm, Cindy Körner, Stefan Wiemann   +10 more
wiley   +1 more source

Large cell neuroendocrine carcinoma transformation: A novel acquired drug resistance mechanism in colorectal adenocarcinoma. [PDF]

Cancer Innov, 2023
Du F, Han Y, Hu X, Xiao Y, Shi Y, Sun J, Sun Z, Yang Y, Yu J, Zhang X, Jia J.   +10 more
europepmc   +1 more source

Sensitivity of Six Tier 1 RTI resistance mutations for detecting transmitted or acquired drug resistance.

, 2016
Cumulative prevalence or sensitivity of the Six Tier 1 RT inhibitor (RTI) drug-resistance mutations (DRMs) for detecting transmitted or acquired drug resistance in viruses from individuals with intermediate or high-level NRTI or NNRTI resistance is shown.
Neil Parkin (273844), Annemarie M. J. Wensing (105565), Rami Kantor (7863), Soo-Yon Rhee (42412), Elliot Raizes (840995), Mark A. Wainberg (196455), Irene Mukui (757883), Douglas D. Richman (168764), Mina C. Hosseinipour (143744), Jonathan M. Schapiro (374093), Joseph E. Fitzgibbon (840997), Marco Schito (840998), Carole L. Wallis (326872), Nicaise Ndembi (703630), Michael R. Jordan (146520), Raph L. Hamers (718072), Avelin F. Aghokeng (322582), Clement Zeh (226174), Gert U. Van Zyl (427181), Michele Tang (840996), Robert W. Shafer (32534), Tobias F. Rinke de Wit (178193), Joseph Fokam (322576), Lisa M. Frenkel (337077), Chunfu Yang (293864), Arlene Chua (134856), Joel E. Gallant (348304), David Katzenstein (182035), Silvia Bertagnolio (57174), Ravindra K. Gupta (372679), Tulio De Oliveira (5666317), Sergio Carmona (562195)   +31 more
core   +1 more source

In vitro and in silico modelling of ROS1‐positive non‐small cell lung cancer reveals fusion‐dependent tyrosine kinase inhibitor responses

Molecular Oncology, EarlyView.
Drug resistance limits treatment success in a subset of lung cancers driven by ROS1 gene alterations. Using patient‐derived cells and computer simulations, we studied three key mutations and how they affect five targeted drugs. The mutations reduced drug effectiveness in different ways by altering protein structure and behavior.
Farhan Ul Haq, Marc Terrones, Felicia Rodrigues Fortes, Anne Schepers, Alessia Denis, Christophe Deben, Ken Op de Beeck, Guy Van Camp, Geert Vandeweyer   +8 more
wiley   +1 more source